Targeting protein clearance pathways in -associated Parkinson disease.
作者信息
Chen Chase, Hertz Ellen, Chen Yu, Sidransky Ellen
机构信息
Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Expert Opin Ther Targets. 2022 Dec;26(12):1031-1035. doi: 10.1080/14728222.2022.2166828. Epub 2023 Jan 12.
Abstract
摘要
相似文献
1
Targeting protein clearance pathways in -associated Parkinson disease.
Expert Opin Ther Targets. 2022 Dec;26(12):1031-1035. doi: 10.1080/14728222.2022.2166828. Epub 2023 Jan 12.
2
Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Trends Neurosci. 2019 Sep;42(9):631-643. doi: 10.1016/j.tins.2019.05.010. Epub 2019 Jul 6.
3
The relationship between glucocerebrosidase mutations and Parkinson disease.
J Neurochem. 2016 Oct;139 Suppl 1(Suppl Suppl 1):77-90. doi: 10.1111/jnc.13385. Epub 2016 Feb 10.
4
The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
J Neurochem. 2020 Jul;154(1):11-24. doi: 10.1111/jnc.14968. Epub 2020 Feb 3.
5
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23.
6
Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Adv Drug Deliv Rev. 2022 Aug;187:114402. doi: 10.1016/j.addr.2022.114402. Epub 2022 Jun 25.
7
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.
Ann Neurol. 2011 Jun;69(6):940-53. doi: 10.1002/ana.22400. Epub 2011 Apr 6.
8
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Pharmacol Ther. 2023 Jun;246:108419. doi: 10.1016/j.pharmthera.2023.108419. Epub 2023 Apr 19.
9
Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
Mov Disord. 2022 Aug;37(8):1782. doi: 10.1002/mds.29136.
10
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Hum Mol Genet. 2023 May 18;32(11):1888-1900. doi: 10.1093/hmg/ddad025.
引用本文的文献
1
Adaptive immunity in the pathogenesis and treatments of Parkinson's disease.
NeuroImmune Pharm Ther. 2025 Jun 20;4(2):273-284. doi: 10.1515/nipt-2025-0008. eCollection 2025 Jun.
2
Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.
ACS Omega. 2025 Jan 8;10(2):1864-1892. doi: 10.1021/acsomega.4c09114. eCollection 2025 Jan 21.
3
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.
Transl Neurodegener. 2024 Sep 12;13(1):48. doi: 10.1186/s40035-024-00437-6.
4
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease.
Int J Mol Sci. 2024 Feb 2;25(3):1827. doi: 10.3390/ijms25031827.
本文引用的文献
1
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease.
Brain. 2023 May 2;146(5):1859-1872. doi: 10.1093/brain/awac413.
2
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
Mov Disord. 2022 Oct;37(10):2134-2139. doi: 10.1002/mds.29190. Epub 2022 Sep 11.
3
Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.
Sci Adv. 2022 Feb 11;8(6):eabm6393. doi: 10.1126/sciadv.abm6393. Epub 2022 Feb 9.
4
PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.
5
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
J Parkinsons Dis. 2022;12(2):557-570. doi: 10.3233/JPD-212714.
6
Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.
Front Neurol. 2021 Jun 14;12:681369. doi: 10.3389/fneur.2021.681369. eCollection 2021.
7
Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques.
Int J Mol Sci. 2021 May 1;22(9):4825. doi: 10.3390/ijms22094825.
8
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.
Br J Clin Pharmacol. 2021 Sep;87(9):3561-3573. doi: 10.1111/bcp.14772. Epub 2021 Mar 2.
9
Distinct alpha-Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells.
J Neurochem. 2021 Mar;156(6):880-896. doi: 10.1111/jnc.15174. Epub 2020 Sep 22.
10
PROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer's and Parkinson's Diseases.
ACS Med Chem Lett. 2020 Apr 28;11(6):1086-1087. doi: 10.1021/acsmedchemlett.0c00192. eCollection 2020 Jun 11.
Zotero 插件